Semax is a commonly searched research peptide with a regulatory status that is easy to misread, because it is an approved medicine in one country and unapproved almost everywhere else. The questions to settle before ordering are the familiar ones: what is it, what does its documentation establish, and what is the regulatory context in Canada. This is a source-based summary. It is not a guide to any use, not a claim that Semax is an authorized drug in Canada or suitable for human use, and not legal or medical advice.

Identity starts with the named compound

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), an analogue of a fragment of adrenocorticotropic hormone (ACTH): its Met-Glu-His-Phe portion corresponds to the ACTH(4–7) fragment, extended by a synthetic Pro-Gly-Pro tail. A procurement record should begin with the compound name, that identity, the selected strength, and the lot, so a receiving laboratory can reconcile what was ordered against the label and the source document. Those fields establish identity for reconciliation; they do not verify biological activity or authorize a route of use, and reference sources note that the mechanism of action of Semax is not established.

Regulatory status: approved in one country is not approved here

Semax has been studied extensively in Russia and appears on the Russian Federation’s List of Vital and Essential Drugs, where it is used as a prescription medicine. Outside Russia, it is a different picture: Semax has not been evaluated, approved for use, or marketed in most other countries, and it is not approved by the United States Food and Drug Administration. It is widely sold by online vendors as a purported nootropic. The load-bearing point for a Canadian laboratory is that approval in one jurisdiction does not make a material an authorized drug in Canada; an unauthorized product here has not been assessed by Health Canada for safety, efficacy, and quality, and a research-use-only label does not confer legal status — the same principle set out in our note on Canadian regulatory context for research peptides. Determining whether a given procurement, possession, import, or use complies with applicable requirements remains the purchaser’s and the receiving laboratory’s responsibility.

What a CoA can and cannot establish

A lot-linked Certificate of Analysis can report measurements such as chromatographic area percentage, observed mass, or other tests performed by the issuing laboratory, and its scope is limited to the sample, methods, and results stated on that document. For Semax as for any compound, the checks are the same:

  • Match the compound, lot, and certificate identifier.
  • Read the method and the actual measured value.
  • Separate chromatographic purity from identity and potency.
  • Do not treat a CoA as regulatory approval, sterility assurance, or a substitute for an end laboratory’s validated controls unless the document expressly supports that conclusion.

Procurement boundary for Canadian laboratories

Before ordering, review the canonical product page, the posted source record, destination restrictions, and the Research-Use-Only Acknowledgement. After receipt, identity reconciliation, storage, preparation, assay design, waste handling, and chain-of-custody remain the receiving laboratory’s responsibility.

For laboratory research use only. Not for human consumption, diagnostic, or therapeutic use. This article summarizes public regulatory and reference sources and is not legal or medical advice.